Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical ...
Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...